Who We Are
Biologics by McKesson specialty pharmacy is a leader in creating truly exceptional patient experiences by simplifying connections for providers and delivering personalized care for every patient who we have the honor of serving.
Video transcripts available here.
We Focus on Our Patients
At Biologics, we focus on why we do what we do: our patients and the partners we work with. As an independent specialty pharmacy, we specialize in cancer and rare disease areas. Our goals are to simplify access to therapies and deliver personalized clinical care that helps patients understand how to take their medication, manage side effects and achieve the best-possible outcomes. We also provide benefits investigation, assist with prior authorizations and help patients find financial aid so they can afford their treatment.
Take a look at what our patients have to say about their experience with us.
Setting the Standard
With over 25 years’ experience caring for patients with cancer and other complex and rare diseases, Biologics has a strong foundation of clinical care with our multidisciplinary care team, and we’ve built on that approach by layering in partnerships, programs and technology that allow us to further elevate the way we care for our patients and the access we can provide them.
What can we help you with today?
For Patients
Quick delivery, financial aid, side-effect management and adherence support.
For Providers
Fast time to first fill, customized solutions and exceptional patient care.
For Biopharma
Fast time to first fill, provider engagement and patient adherence.
For Payers
Cost management, industry-leading access and clinical care.
Biologics by McKesson News
LUMAKRAS (sotorasib), FDA Approved for Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., June 11, 2021 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Amgen Oncology as a specialty...
Cholangiocarcinoma Foundation Q&A
1. What is the Cholangiocarcinoma Foundation? Like many non-profit organizations, a tragedy was the driving force behind the launch of the Cholangiocarcinoma Foundation. Stacie Lindsey,...
NULIBRY (fosdenopterin), First and Only FDA-Approved Therapy to Reduce the Risk of Mortality in Patients with Molybdenum Cofactor Deficiency Type A, Available Exclusively at Biologics by McKesson
CARY, N.C., April 19, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Origin Biosciences, Inc., an affiliate...
